

The Antibacterial Effect of Low Temperature Stored Amnion on Growth of Escherichia Coli, Staphylococcus Aureus and Pseudomonas Aeruginosa

F.A. Tehrani (MSc)¹, S. Azizian (MSc)², KH. Modaresifar (MSc)², H. Peirovi (MD)³, H. Niknejad (PhD)^{1*}

1.Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, I.R.Iran

2.Department of Biomaterials, Faculty of Biomedical Engineering, Amirkabir University of Technology, Tehran, I.R.Iran

3.Department of Surgery, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, I.R.Iran

J Babol Univ Med Sci; 20(1); Jan 2018; PP:13-19

Received: Jan 21st 2017, Revised: Sep 6th 2017, Accepted: Nov 21st 2017.

ABSTRACT

BACKGROUND AND OBJECTIVE: Amniotic membrane (AM) has a lot of applied properties like anti-bacterial characteristic mediated by peptides such as elafin. Because of limitations in use of freshly prepared tissue, there are various methods for long-term preservation of amniotic membrane. This study was conducted to determine the effect of cryopreservation, as one of the common methods of preservation of amniotic membrane, on its antibacterial property against the growth of commonly occurring bacteria in the clinic.

METHODS: In this experimental study, the effect of fresh AM (from elective Cesarean) and cryopreserved (by 10% DMSO) AM on the growth of three standard bacterial strains including Escherichia coli ATCC 25922, Staphylococcus aureus, Pseudomonas aeruginosa and two clinical isolated strains of E.coli were evaluated using disk diffusion test. In this method, pieces of fresh or cryopreserved AM was placed in the culture plate after bacterial culturing. After incubation, the number of plates with inhibition zone and amount of inhibition zone were measured. The amount of elafin was measured in AM samples using ELISA.

RESULTS: Fresh AM inhibit the growth of Pseudomonas aeruginosa and two clinical isolated strains of E.coli. However, it has no effect on the growth of standard strain of Escherichia coli and Staphylococcus aureus strain. There is no difference in the number of plates including inhibition zone between fresh and cryopreserved AM. The amount of elafin decreased significantly in cryopreserved AM ($p < 0.01$).

CONCLUSION: The results of this study showed that the anti-bacterial property of the AM depends on bacterial species. In addition, the cryopreservation process maintains anti-bacterial properties of amniotic stem cells.

KEY WORDS: Amniotic membrane, Anti-bacterial, Cryopreservation, Bacterial strain.

Please cite this article as follows:

Tehrani FA, Azizian S, Modaresifar KH, Peirovi H, Niknejad H. The Antibacterial Effect of Low Temperature Stored Amnion on Growth of Escherichia Coli, Staphylococcus Aureus and Pseudomonas Aeruginosa. J Babol Univ Med Sci. 2018; 20(1):13-19.

*Corresponding Author; H. Niknejad (PhD)

Address: Department of Pharmacology, Faculty of Medicine, Koodakyar St, Daneshjoo Blvd, Velenjak, Tehran, I.R.Iran.

Tel: +98 21 22439969.

E-mail: niknejad@sbmu.ac.ir

Introduction

Over the years, embryonic membranes have been one of the substitute tissues used in surgery (1-3). The amniotic membrane is the innermost layer of the embryonic membrane consisting of five layers of epithelial layer, basal membrane, inner compact layer, fibroblastic layer and outermost spongy layer, and has unique properties (4). This tissue can affect angiogenesis (5), induces apoptosis (6) and reduces inflammatory and immune responses (7, 8). Also, having antimicrobial properties can inhibit the growth of bacteria, viruses and fungi (9, 10).

Cellular matrix compounds in the basal membrane of the amniotic membrane are a natural scaffold for cell culture and use in tissue engineering (11, 12). Amniotic membranes contain a large number of human stem cells that can be used widely. Access to this tissue is easy and there are no moral issues for use (13, 14). One of the important properties of amniotic membrane is its antimicrobial property, which has many clinical applications (15).

Antimicrobial properties of amniotic membrane are due to antimicrobial peptides, including Defensins, SLPI, and Elafin. These molecules are produced and secreted at mucosal surfaces and often by epithelial cells. "Whey acidic peptide (WAP)" is a group of antimicrobial peptides in amniotic membranes that include Elafin and SLPIs (16). These molecules are low-weight and have anti-protease activity (16, 17) and elastase inhibition (18-20), and as components of the innate immune system, controlling the inflammatory response at mucosal surfaces, and protect the surface associated with infection. (20). Human Beta-Defensins are another group of peptides that contribute to the development of immune responses to amniotic membrane (17). One of the common methods of using amniotic membrane in the clinic is the use of fresh tissue that is immediately isolated after delivery. One of the limitations of using the fresh amniotic membrane is its rapid destruction. The cells in this tissue survive shortly after delivery and, in addition, due to the presence of latency period, it is possible to transmit some diseases when using fresh tissue. Therefore, methods have been proposed to preserve the amniotic membrane. Cryopreservation is one of the common methods for long-term amniotic membrane maintenance. In this method, using different concentrations of preservatives such as glycerol and Dimethyl sulfoxide, tissue can be stored for months at temperatures of -80°C or -196°C.

Although cryopreservation can affect its properties by affecting the cells and tissue structure of the amniotic membrane (21, 22) due to the limited access to fresh tissue it is necessary to investigate the effect of maintenance methods on the properties of amniotic membrane. In this study, the effect of Cryopreservation on antibacterial properties of amniotic membrane has been investigated.

Methods

This experimental study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences by code of: IR.SBMU. MSP.REC.1394.139 In order to isolate and prepare the amniotic membrane, the placenta tissue obtained from elective cesarean section of healthy women without antibiotic use during pregnancy during 38-40 weeks of pregnancy was prepared from the Erfan Hospital in Tehran under sterile conditions. The placenta samples were transferred to the lab in a container containing sterile saline phosphate buffer at temperature of 4°C. All stages of isolation and preparation of amniotic membrane samples were performed in sterile conditions. The amniotic membrane was separated mechanically from the chorion and washed several times with cold saline phosphate buffer to remove the remaining blood, so that there was no trace of blood stains on it. In order to cryopreservation of amniotic membrane, samples of this tissue after isolation and washing, were stored at -80 °C for 6 months in sterile saline phosphate buffer containing 10% dimethyl sulfoxide (Merck, Germany) and 10% Bovine serum (Gibco, USA) and 10% Dubbelco's modified Eagle medium (DMEM)/F12 (Gibco, USA).

After this period, the samples were gotten out from frozen at room temperature and were washed three times with sterile saline phosphate buffer and then cut to pieces of about 1 cm². In order to study the antibacterial effects of amniotic membrane, direct disk diffusion method was used on 3 standard strains including *Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 25923, *Pseudomonas aeruginosa* ATCC 27853 and two clinical strains of *E. coli* T3 and *E. coli* T4). Clinical strains were prepared from patients of Ayatollah Taleghani Hospital in Tehran. Standard strains were selected according to the guidelines of the Standard Institute of Laboratory and Clinical; meanwhile, all stages of the work were carried out in accordance with the terms of this protocol (23). The

bacteria were first cultured on blood agar (Merck) as a common culture medium and incubated for 24 hours at 37°C. Isolated colonies were prepared with 0.5 McFarland concentration ($1.5 \times 10^8 \times \text{CFU}$) in normal saline and were cultured on the muller Hinton agar (Merck), as a selectable medium. Then, the pieces made from fresh amniotic membrane and cryopreserved AM were placed in bacterial culture plates and the plates were incubated for 24 hours at 37 °C. After this time, the size of the inhibition zone was measured in all the plates (in millimeters) and the amount of inhibition zone around the amniotic membrane was compared. One sample of each tissue was placed on a plate containing Muller Hinton Agar as a control group to determine the probability of contamination of the amniotic membrane after maintenance. After preparing the amniotic membrane, a 5×5 cm piece of fresh tissue and cryopreserved AM was isolated and, after crushing, 10 ml of normal saline buffer was added. Tissue extracts were obtained using a 80-watt sonication with 0.5 second intervals of 12 minutes. The samples were then centrifuged at 1000 rpm for 5 minutes. The collected supernatant was then centrifuged for 2 minutes at 8000 rpm.

Finally, the amount of Elafin (in pg/ml) in the supernatant was measured using an ELISA kit (Abcam, USA) based on the manufacturer's instructions to compare the amount of Elafin present in the fresh tissue and cryopreserved AM supernatant. The results are reported as Mean±SEM. For statistical analysis, GraphPad Prism software version 5.04 was used and one-way ANOVA and Tukey test were used and $p < 0.05$ was considered significant.

Results

In this study, antibacterial activity of fresh amniotic membrane and cryopreserved AM on 5 strains of bacteria including *Staphylococcus aureus* ATCC 25923, *Pseudomonas aeruginosa* ATCC 27853, *Escherichia coli* ATCC 25922 and two clinical strains of *Escherichia coli* (T3, T4) were investigated by disc diffusion method. An inhibitory effect was observed below and around the edges of the fresh amniotic membrane in *Pseudomonas aeruginosa* ATCC 27853 and two clinical strains of *E. coli* (T3, T4) after 24 hours incubation (Fig 1a,b,c). This inhibitory effect was also seen in cryopreserved AM. Inhibitory effect of amniotic membrane stored at -80 °C in *Pseudomonas aeruginosa* ATCC 27853 and two clinical strains of *E. coli* (T3, T4) are shown in Figs.

1D, 1E and 1F. No growth was seen in the control group (Fig 1G). Unlike other tested strains, there was no inhibitory effect on *Staphylococcus aureus* ATCC 25923 and *Escherichia coli* ATCC 25922 strains (Fig H, I).




Figure 1. (A, B and C) The formation no growth inhibition zone in the vicinity of the fresh AM: a) *Pseudomonas aeruginosa* ATCC 27853; b) *Escherichia coli* T3; c) *Escherichia coli* T4. (T, E and C) The formation inhibition zone in the vicinity of the Cryopreserved AM: d) *Pseudomonas aeruginosa* ATCC 27853; E) E3; E3) *Escherichia coli* T4. (C) Cultivation of AM control. (No colony was found.). G) *Escherichia coli* ATCC25922 cultivated with fresh AM; (h) *Staphylococcus aureus* ATCC25923 cultivated with fresh AM. (No growth inhibition zone was observed in *staphylococcus aureus* ATCC25923 and *E. coli* ATCC25922)

The number of plates with no growth inhibition zone under the amniotic membrane showed no significant difference between fresh tissues and cryopreserved tissue (Table 1) (Fig 2a). The growth inhibition zone around the edges of cryopreserved AM was similar to the fresh tissue in this study. The fresh amniotic membrane that cultured in the plate with *Pseudomonas aeruginosa* and the two clinical strains of *E. coli* (T3, T4) formed the inhibition zone. The highest inhibition growth zones created by fresh tissue in a *Pseudomonas aeruginosa* cultured plate was 5 ± 1.1 mm, which significantly decreased in *E. coli* (T3, T4) cultures ($p < 0.001$). In addition, the size of the inhibition zone in cryopreserved AM was significantly reduced in comparison with fresh samples in *pseudomonas aeruginosa* cultures ($p < 0.01$), which, was not observed in *Escherichia coli* (T3, T4) (Fig. 2b). The results showed that the amount of Elafin in fresh tissue was significantly higher than cryopreserved tissue (Table 2) ($p < 0.01$) (Fig. 2c).

Table 1. Comparison of antibacterial effects in cryopreserved tissue with fresh one

Bacterial strain	Cryopreserved tissue		Fresh tissue	
Pseudomonas aeruginosa ATCC 27853	growth retardation under the tissue [†] (n=11)	no growth inhibition zone [^] (n=11)	growth retardation under the tissue [†] (n=14)	no growth inhibition zone [^] (n=14)
	11	*7,*4	14	*2,*12
Escherichia coli T3	growth retardation under the tissue [†] (n=11)	no growth inhibition zone [^] (n=12)	growth retardation under the tissue [†] (n=19)	no growth inhibition zone [^] (n=21)
	*7,*4	*7,*5	*14,*5	*19,*2
Escherichia coli T4	growth retardation under the tissue [†] (n=11)	no growth inhibition zone [^] (n=11)	growth retardation under the tissue [†] (n=15)	no growth inhibition zone [^] (n=14)
	*7,*4	*6,*5	*12,*3	*12,*2

†The number of studied plates in terms of a growth retardation under the tissue, * the number of studied plates in terms of no growth inhibition zone

★The number of plates with no growth inhibition zone, ★ The number of plates with growth inhibition zone




Figure 2. (a) Comparison of the percentage of plates with no growth inhibition zone to the total number of plates around the fresh and cryoprecipitated AM based on the cultivated bacterial species. (B) The mean size of no growth inhibition zone in millimeters (mm) in *Pseudomonas aeruginosa* and *Escherichia coli* T3 and T4 appeared 24 hours after incubation in vicinity to the fresh and cryoprecipitated AM (** $p < 0.01$ and *** $p < 0.001$). (C) The amount of oligin present in the fresh and cryoprecipitated AM (** $p < 0.01$)

Table 2. Effect of processing methods on mean and maximum of no growth inhibition zone in three strains of bacteria

Group	Cryopreserved tissue		fresh tissue	
	Max of inhibition zone (mm)	Mean of inhibition zone (mm)	Max of inhibition zone (mm)	Mean of inhibition zone (mm)
Pseudomonas aeruginosa ATCC 27853	3	1.5(n=11)	5	2.8(n=14)
Escherichia coli T3	1	0.8(n=12)	2	1.2(n=21)
Escherichia coli T4	1	0.9(n=11)	2	1.3(n=14)

Discussion

Based on the results of this study, the fresh amniotic membrane in plates with *Pseudomonas aeruginosa* ATCC 27853 and the two clinical strains of *E. coli* T3 and T4 caused a inhibition growth zone. However, there was no inhibitory effect on the growth of *Staphylococcus aureus* ATCC25923 and *E. coli* ATCC25922 below and around the amniotic membrane. These results indicate that the antibacterial effect of amniotic membrane is dependent on the genus and strain of bacteria that confirmed by Kjaegaarda et al. Kjaegaarda et al. have reported the existence of a narrow inhibition zone (about 1 mm) around the amniotic membrane in the vicinity of group A *Streptococcus* and *Streptococcus saprophyticus* (9). The largest extent of the inhibition growth zone in this study was related to *Pseudomonas aeruginosa* (about 5 mm). Differences in the amount of inhibition growth zone and the type of bacteria can be attributed to the different structure of the bacteria (24). For example, Elafin, which is an amniotic antimicrobial peptide, inhibits one of the virulence factors of *Pseudomonas aeruginosa* called serine peptidase (25). Therefore, it seems that the effect of this tissue on *pseudomonas aeruginosa* was more pronounced.

Although antibacterial effects of tissues such as amniotic and chorion (26), which are of great importance in the treatment of burns (27) and ocular diseases (28), have been shown in previous studies, so far little studies have been done on the effect of the preserving method on the properties of these tissues. The results showed that the cryopreservation of amniotic membrane significantly reduced the amount of Elafin compared to fresh tissue. In previous studies,

it has been shown that the viability of amniotic membrane epithelial cells is reduced by about 50% after freezing (21, 29), despite decreasing the cellular viability and reducing the amount of Elafin, is still retained by the amniotic membrane antibacterial properties. Therefore, in addition to secretion peptides from amniotic membrane cells, other factors can also contribute to its antibacterial properties. Antimicrobial peptides in the amniotic membrane, such as lactoferrin (30) and extracellular matrix components, can contribute to the anti-bacterial property of cryopreserved tissue. For example, hyaluronic acid in the extracellular matrix of amnion can inhibit *Enterococci*, *Streptococcus mutans*, two strains of *Escherichia coli* and *Pseudomonas aeruginosa* depending on the growth concentration (30). The results of this study showed that cryopreservation maintenance method was able to maintain the antibacterial properties of amniotic membrane and antibacterial properties of amniotic membrane was dependent on bacterial strain that could allow the use of cryopreserved AM in the clinic. Further studies are needed to investigate the antimicrobial properties of amniotic membrane and its clinical applications.

Acknowledgments

Hereby, we would like to thank the management and personnel of the surgery room of the Erfan Hospital to cooperate in the investigation. This research has been funded by the Grant Committee of the National Institute for Medical Research Development of Iran (Naimad) under the project number 958796.

References

1. Peirovi H, Rezvani N, Hajinasrollah M, Mohammadi SS, Niknejad H. Implantation of amniotic membrane as a vascular substitute in the external jugular vein of juvenile sheep. *J Vasc Surg.* 2012;56(4):1098-104.
2. Fernandes M, Sridhar MS, Sangwan VS, Rao GN. Amniotic membrane transplantation for ocular surface reconstruction. *Cornea.* 2005;24(6):643-53.
3. Yildiz EH, Nurozler AB, Ozkan Aksoy N, Altiparmak UE, Onat M, Karaguzel H. Amniotic membrane transplantation: indications and results. *Eur J Ophthalmol.* 2008;18(5):685-90.
4. Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. *Surv Ophthalmol.* 2004;49(1):51-77.
5. Niknejad H, Paeini-Vayghan G, Tehrani FA, Khayat-Khoei M, Peirovi H. Side dependent effects of the human amnion on angiogenesis. *Placenta.* 2013;34(4):340-5.
6. Niknejad H, Khayat-Khoei M, Peirovi H, Abolghasemi H. Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumor therapeutic strategy. *Cytotherapy.* 2014;16(1):33-40.
7. Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. *Cornea.* 2000;19(3):348-52.
8. Hori J, Wang M, Kamiya K, Takahashi H, Sakuragawa N. Immunological characteristics of amniotic epithelium. *Cornea.* 2006;25(10):53-8.
9. Kjaergaard N, Hein M, Hyttel L, Helmig RB, Schønheyder HC, Uldbjerg N, et al. Antibacterial properties of human amnion and chorion in vitro. *Eur J Obstet Gynecol Reprod Biol.* 2001;94(2):224-9.
10. Tehrani F A, Ahmadiani A, and Niknejad H. The effects of preservation procedures on antibacterial property of amniotic membrane. *Cryobiol.* 2013;67(3):293-8.
11. Deihim T, Yazdanpanah G, Niknejad H. Different light transmittance of placental and reflected regions of human amniotic membrane that could be crucial for corneal tissue engineering. *Cornea.* 2016;35(7):997-1003
12. Kakavand M, Yazdanpanah G, Ahmadiani A, Niknejad H. Blood compatibility of human amniotic membrane compared with heparin-coated ePTFE for vascular tissue engineering. *J Tissue Eng Regen Med.* 2017;11(6):1701-9.
13. Niknejad H, Yazdanpanah G, Ahmadiani A. Induction of apoptosis, stimulation of cell-cycle arrest and inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer. *Cell Tissue Res.* 2016;363(3):599-608.
14. Niknejad H, Deihim T, Ahmadiani A, Jorjani M, Peirovi H. Permanent expression of midbrain dopaminergic neurons traits in differentiated amniotic epithelial cells. *Neurosci Lett.* 2012;506(1):22-27.
15. Talmi YP, Sigler L, Inge E, Finkelstein Y, Zohar Y. Antibacterial properties of human amniotic membranes. *Placenta.* 1991;12(3):285-8.
16. Sallenave JM. Antimicrobial activity of antiproteinases. *Biochem Soc Trans.* 2002;30(2):111-5.
17. King AE, Paltoo A, Kelly RW, Sallenave JM, Bocking AD, Challis JR. Expression of natural antimicrobials by human placenta and fetal membranes. *Placenta.* 2007;28(2-3):161-9.
18. Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM. Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater.* 2008;15:88-99.
19. Stock SJ, Kelly RW, Riley SC, Calder AA. Natural antimicrobial production by the amnion. *Am J Obstet Gynecol.* 2007;196(3):255.
20. King AE, Critchley HO, Sallenave JM, Kelly RW. Elafin in human endometrium: an antiprotease and antimicrobial molecule expressed during menstruation. *J Clin Endocrinol Metab.* 2003;88(9):4426-31.
21. Niknejad H, Deihim T, Solati-Hashjin M, Peirovi H. The effects of preservation procedures on amniotic membrane's ability to serve as a substrate for cultivation of endothelial cells. *Cryobiology.* 2011;63(3):145-51.
22. Yazdanpanah G, Paeini-Vayghan G, Asadi S, Niknejad H. The effects of cryopreservation on angiogenesis modulation activity of human amniotic membrane. *Cryobiology.* 2015;71(3):413-8.
23. Institue C a LS. Performance Standards for Antimicrobial Disk Susceptibility. 2006;26(1):1-59.

24. Niknejad H, Asi Tehrani F, Peirovi H, Abolghasem H. The sources of microbial contamination of stem cells of application in cell therapy. J Babol Univ Med Sci. 2014;16:95-105.[In Persian]
25. Bellemare A, Vernoux N, Morisset D, Bourbonnais Y. Human pre-elafin inhibits a *Pseudomonas aeruginosa*-secreted peptidase and prevents its proliferation in complex media. Antimicrob Agents Chem. 2008;52(2):483-90.
26. Zare Bidaki M, Lessani T, Khazaie Z. Evaluation of anti-bacterial effects of chorionic membranes in vitro. J Birjand Univ Med Sci. 2012;19(2):140-7. [In Persian].
27. Niknejad H, Yazdanpanah G. Anticancer effects of human amniotic membrane and its epithelial cells. Med Hypotheses. 2014;82(4):488-9.
28. Gomes JA, Romano A, Santos MS, Dua HS. Amniotic membrane use in ophthalmology. Curr Opin Ophthalmol. 2005;16(4):233-40.
29. Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest Ophthalmol Vis Sci. 2001;42(7):1539-46.
30. Kanyshkova TG, Buneva VN, Nevinsky GA. Lactoferrin and its biological functions. Biochemistry. Biokhimiia. 2001;66(1):1-7.